Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Jeste, D. V. Articles by Caligiuri, M. P. Search for Related Content PubMed Citation Articles by Jeste, D. V. Articles by Caligiuri, M. P. Geriatric Psychiatry Other Neuropsychiatric Disorders Other Neuroleptics

Incidence of Tardive Dyskinesia in Early Stages of Low-Dose Treatment With Typical Neuroleptics in Older Patients

OBJECTIVE: The authors studied the risk of tardive dyskinesia for older patients in the early stages of treatment with typical neuroleptics. METHOD: They examined the cumulative incidence of tardive dyskinesia 1, 3, 6, 9, and 12 months after the institution of neuroleptic therapy among 307 psychiatric outpatients over age 45. The patients' median dose was 68.4 mg/day of chlorpromazine equivalent. RESULTS: In the patients who had never received neuroleptics at baseline (N=87), the mean cumulative incidence of tardive dyskinesia was 3.4% and 5.9% at 1 and 3 months, respectively. There was no significant difference in the 12-month cumulative incidence of tardive dyskinesia among patients who had been neuroleptic-naive at baseline (22.3%) and the 89 patients who had received neuroleptics before baseline for 1–30 days (24.6%); however, the 131 patients who had received neuroleptics before baseline for more than 30 days tended to have a greater cumulative 12-month incidence of tardive dyskinesia (36.9%). CONCLUSIONS: The risk of tardive dyskinesia in older outpatients is high, even with relatively short treatment with low doses of conventional neuroleptics.

This article has been cited by other articles:

				R. A. Rosenheck, D. L. Leslie, J. L. Sindelar, E. A. Miller, P. N. Tariot, K. S. Dagerman, S. M. Davis, B. D. Lebowitz, P. Rabins, J. K. Hsiao, et al. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease Arch Gen Psychiatry, November 1, 2007; 64(11): 1259 - 1268. [Abstract] [Full Text] [PDF]

				References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]

				G. REMINGTON Rational pharmacotherapy in early psychosis The British Journal of Psychiatry, August 1, 2005; 187(48): s77 - s84. [Abstract] [Full Text] [PDF]

				C. U. CORRELL, J. M. KANE, and S. LEUCHT Dr. Correll and Colleagues Reply Am J Psychiatry, February 1, 2005; 162(2): 405 - 406. [Full Text] [PDF]

				C. U. Correll, S. Leucht, and J. M. Kane Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies Am J Psychiatry, March 1, 2004; 161(3): 414 - 425. [Abstract] [Full Text] [PDF]

				D. Taylor Low dose typical antipsychotics - a brief evaluation Psychiatr. Bull., December 1, 2000; 24(12): 465 - 468. [Full Text]

				D. V. Jeste, A. Okamoto, J. Napolitano, J. M. Kane, and R. A. Martinez Low Incidence of Persistent Tardive Dyskinesia in Elderly Patients With Dementia Treated With Risperidone Am J Psychiatry, July 1, 2000; 157(7): 1150 - 1155. [Abstract] [Full Text]

				E.-K. Tan and J. Jankovic Tardive and idiopathic oromandibular dystonia: a clinical comparison J. Neurol. Neurosurg. Psychiatry, February 1, 2000; 68(2): 186 - 190. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us